Pharmaust Limited (ECQ0) Price & Analysis

3 Followers

ECQ0 Stock Chart & Stats

€0.04

€0.00(0.00%)

At close: Jan 08 4:00 PM EST

€0.04

€0.00(0.00%)

Day’s Range― - ―

52-Week Range€0.02 - €0.09

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€36.66M

Enterprise Value€36.12

Total Cash (Recent Filing)€12.71M

Total Debt (Recent Filing)€3.31M

Price to Earnings (P/E)―

Beta0.91

Next Earnings

Mar 03, 2027

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.02

Shares Outstanding791,652,340

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.06

Price to Book (P/B)2.87

Price to Sales (P/S)2.08

P/FCF Ratio-2.43

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€0.12

Price Target Upside209.06% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Improved CapitalizationThe substantial increase in equity and assets gives Pharmaust a larger financial cushion than it had in 2025. Although losses remain significant, stronger capitalization can improve resilience, support ongoing development activities, and provide more flexibility in managing future funding needs.

Narrower Annual LossThe reduction in annual net loss indicates some improvement in the company’s financial trajectory, even though profitability remains distant. If maintained, a smaller loss could slow equity depletion, reduce funding pressure, and create a better base for future operating discipline.

Reduced Cash Burn Versus 2025A smaller free-cash-flow deficit in 2026 is a modest improvement in cash management relative to the prior year. Sustaining this direction would extend the company’s funding runway and lessen the pace at which external capital is required, despite continued substantial cash outflows.

Bears Say

Revenue Has Fallen To ZeroThe absence of reported revenue across three consecutive years leaves Pharmaust without demonstrated commercial traction in the period covered. This weakens the foundation for self-funded growth, limits operating leverage, and makes future progress more dependent on successful commercialization or external financing.

Severe And Persistent Cash BurnPersistent negative operating and free cash flow shows that the business is not currently funding its activities internally. The scale of recent outflows can accelerate reliance on capital raising or borrowing, while also limiting flexibility to invest in development and absorb setbacks.

Renewed Borrowing Amid Ongoing LossesNew debt alongside continued negative returns on equity indicates that the stronger capitalization has not yet translated into sustainable profitability. Borrowing adds repayment and financing obligations, while ongoing losses can continue eroding shareholder value and constrain future capital allocation.

Pharmaust Limited News

Neurizon Director Boosts Shareholding in On-Market Purchase

Pharmaust Limited ( ($AU:NUZ) ) just unveiled an update. Neurizon Therapeutics has disclosed a change in director Sergio...

2h ago

Neurizon Therapeutics Redeems 1 Million Convertible Notes Without Conversion

Pharmaust Limited ( ($AU:NUZ) ) just unveiled an announcement. Neurizon Therapeutics Limited has announced the cessation of 1,000,000...

2d ago

Neurizon Cuts Convertible Notes and Locks In Standstill as HEALEY ALS Trial Funding Secured

An announcement from Pharmaust Limited ( ($AU:NUZ) ) is now available. Neurizon Therapeutics will redeem 1,000,000 convertible notes...

7d ago

Neurizon Therapeutics Seeks ASX Quotation for 7.4 Million New Shares

Pharmaust Limited ( ($AU:NUZ) ) has provided an announcement. Neurizon Therapeutics Limited has applied for quotation of 7,436,765...

7d ago

NIH Backs Neurizon’s NUZ-001 ALS Access Program With Multimillion-Dollar Grant

An update from Pharmaust Limited ( ($AU:NUZ) ) is now available. Neurizon Therapeutics has secured participation in a...

8d ago

Neurizon names seasoned pharma executive Chris Bremer as CEO ahead of key ALS trial readout

An update from Pharmaust Limited ( ($AU:NUZ) ) is now available. Neurizon Therapeutics has appointed Dr Chris Bremer...

10d ago

Neurizon Therapeutics Expands ASX Quoted Share Base

Pharmaust Limited ( ($AU:NUZ) ) has provided an update. Neurizon Therapeutics Limited has applied for quotation on the...

22d ago

Neurizon Therapeutics files ASX governance disclosure for 2026

An update from Pharmaust Limited ( ($AU:NUZ) ) is now available. Neurizon Therapeutics Limited has lodged its corporate...

23d ago

Neurizon Therapeutics Narrows Loss and Strengthens Balance Sheet in 2026

Pharmaust Limited ( ($AU:NUZ) ) has issued an update. Neurizon Therapeutics Limited has reported a sharply improved financial...

23d ago

Neurizon Therapeutics Issues Large Tranche of Unquoted Incentive Securities

An update from Pharmaust Limited ( ($AU:NUZ) ) is now available. Neurizon Therapeutics Limited has notified the market...

24d ago

ECQ0 FAQ

What was Pharmaust Limited’s price range in the past 12 months?

Pharmaust Limited lowest stock price was €0.02 and its highest was €0.09 in the past 12 months.

What is Pharmaust Limited’s market cap?

Pharmaust Limited’s market cap is €36.66M.

When is Pharmaust Limited’s upcoming earnings report date?

Pharmaust Limited’s upcoming earnings report date is Mar 03, 2027 which is in 167 days.

How were Pharmaust Limited’s earnings last quarter?

Pharmaust Limited released its earnings results on Aug 27, 2026. The company reported -€0.004 earnings per share for the quarter.

Is Pharmaust Limited overvalued?

According to Wall Street analysts Pharmaust Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Pharmaust Limited pay dividends?

Pharmaust Limited does not currently pay dividends.

What is Pharmaust Limited’s EPS estimate?

Pharmaust Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Pharmaust Limited have?

Pharmaust Limited has 791,652,340 shares outstanding.

What happened to Pharmaust Limited’s price movement after its last earnings report?

Pharmaust Limited reported an EPS of -€0.004 in its last earnings report. Following the earnings report the stock price went down -4%.

Which hedge fund is a major shareholder of Pharmaust Limited?

Currently, no hedge funds are holding shares in DE:ECQ0

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Pharmaust Limited Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

490.10%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Pharmaust Limited

Neurizon Therapeutics Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases. The company develops drug discovery intellectual property for the treatment of neurological diseases. Its lead candidate is NUZ-001, a small molecule drug which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, as well as to treat other neurodegenerative diseases. The company was formerly known as PharmAust Limited and changed its name to Neurizon Therapeutics Limited in October 2024. Neurizon Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.

Pharmaust Limited (ECQ0) Earnings & Revenues

Historic Earnings Reports

ECQ0 Stock 12 Month Forecast

Average Price Target

€0.12

▲(209.06% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","1":"€1","-1":"-€1","-0.5":"-€0.5","0.5":"€0.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":0.1236228,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€0.12</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.1236228,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€0.12</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.1236228,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€0.12</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.5,0,0.5,1],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.024,0.03166329230769231,0.039326584615384616,0.04698987692307693,0.05465316923076924,0.06231646153846154,0.06997975384615385,0.07764304615384615,0.08530633846153847,0.09296963076923079,0.10063292307692309,0.1082962153846154,0.1159595076923077,{"y":0.1236228,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.024,0.03166329230769231,0.039326584615384616,0.04698987692307693,0.05465316923076924,0.06231646153846154,0.06997975384615385,0.07764304615384615,0.08530633846153847,0.09296963076923079,0.10063292307692309,0.1082962153846154,0.1159595076923077,{"y":0.1236228,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.024,0.03166329230769231,0.039326584615384616,0.04698987692307693,0.05465316923076924,0.06231646153846154,0.06997975384615385,0.07764304615384615,0.08530633846153847,0.09296963076923079,0.10063292307692309,0.1082962153846154,0.1159595076923077,{"y":0.1236228,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.075,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.058,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.073,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.052,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.044,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.047,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.048,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.039,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.057,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.03,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.027,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.028,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.024,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >